Seoul Economic Daily EnglishDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 14:07:23(首尔 15:07)·⟳ 抓取 14:25:45 +18m22s·⚡ 决策 09-15 14:39:55 +14m10s·42.1 天前
HLB子公司Elevar就胆管癌新药lirafugratinib向EMA递交上市申请，FDA裁决10天后到期
本次EMA申报是继FDA NDA后的程序性地理扩展，沿用既有I/II期数据、无新增临床或商业信息，EMA审评周期1-2年、不产生近期现金流，属低surprise软里程碑；真正的定价催化剂是10天后（9月25/27日）的FDA PDUFA二元裁决，且明日有FOMC。在此之前以EMA申报追入，是用近端波动去赌一个10天后的二元结果；叠加公司核心产品rivoceranib+camrelizumab于2026年7月刚收到FDA CRL的情绪/审查风险，以及韩国市场当前已收盘、下一交易时段才能成交，edge与可执行性均不足。
📄 原文Seoul Economic Daily English↗ 原文
HLB Files for European Approval of Bile Duct Cancer Drug
Seoul Economic Daily Skip to main content Seoul Economic Daily Seoul Economic Daily KST Seoul Economic Daily Korea's Le…
不做 HLB（028300.KQ）
EMA递件为预期内程序性进展（无新数据、EMA收入在1-2年后），真正的二元催化是9月25/27日FDA PDUFA，且次日有FOMC；同子公司7月刚收FDA CRL、韩国当前已收盘须等下一交易时段，追入风险收益不足。不在EMA消息上开仓，等FDA受理/批准或CRL落地作为独立事件再研判（若届时批准且有正surprise再评估做多，若CRL则评估做空/风险）。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
HLB就胆管癌药lirafugratinib向EMA递件是预期内的程序性进展，无新数据、无近期收入；市场真正的关口是9月25/27日FDA裁决，在二元事件和FOMC前追入风险收益不佳，故回避，等FDA结果再判。
消息传播链
- Elevar于9月14日向EMA提交lirafugratinib MAA（公司披露的申报行为），尚未见公司英文新闻稿原文，EMA受理待确认
- 韩媒率先报道EMA递件并附临床数据；此时韩国股市已收盘（15:30），价格反应最早体现在9月16日KST交易时段市场反应:韩国已收盘，尚无本消息驱动的成交；行情工具超时未能取价
- FDA已受理lirafugratinib NDA并给予优先审评，PDUFA目标日9月27日（韩媒稿称25日）——确认真正的近期催化是FDA裁决而非EMA递件
- 同一子公司核心产品rivoceranib+camrelizumab一线肝癌收到FDA CRL，构成HLB监管情绪与生产核查的负面背景
关键理由
- EMA MAA递交仅把资产从'已向FDA申报'推进到'美欧双报'，不改变获批状态，且数据（ORR 46.5%/mOS 22.8个月）为旧数据，增量信息小
- lirafugratinib的价值实现锚定10天后FDA PDUFA；EMA路径对收入贡献在1-2年以后，当前不构成独立可交易催化
主要风险
- 若FDA在9月25/27日如期批准，HLB可能显著向上，回避将错过该涨幅——但那是下一个事件，不应以EMA递件提前裸赌
- 7月rivoceranib+camrelizumab的FDA CRL反映生产/核查层面的尾部风险，可能拖累同子公司lirafugratinib审评，方向存在不确定性
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-10 · 影响 weakens
同子公司核心产品7月收到FDA CRL，构成监管/生产核查负面overhang，削弱仅凭EMA递件做多的安全边际
检索:HLB Elevar rivoceranib camrelizumab FDA CRL complete response letter 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-09-15 · 影响 weakens
EMA申报沿用既有I/II期数据、无新数据，EMA标准审评约1-2年，无近期收入增量，属软里程碑
检索:lirafugratinib EMA filing new clinical data revenue timing 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足+近端二元事件，支持不就EMA递件开仓，等待9月25/27日FDA结果作为独立事件再研判
方向:无可直接定价的对齐样本：生物药企'继FDA后向EMA递交MAA'通常是低surprise程序性事件，市场反应一般温和，真正波动集中在PDUFA/CRL；但未取得经日线验证的同主体先例，不能据此量化幅度
涨幅量级:缺少锚点干净的同市场（韩股）同相位先例，无法可靠设定tp/sl；且行情工具超时，无实时价作基准
形态:程序性多国申报常见'申报日小涨/无反应、价值在裁决日重估'，但本轮未用event_study验证，不作为交易依据
工具执行结果 · 成功 3 · 降级 2 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 27 ms
{"result": "search_processed_events:agent query=`hlb elevar lirafugratinib europe approval filing fgfr2 cholangiocarcinoma | hlb lirafugratinib ema marketing authorization application bile duct cancer | hlb lirafugratinib fda nda`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools HTTP · 10 ms
{ - stock_quote 降级 stock_tools HTTP · 10,171 ms
取价失败: TimeoutError: - web_search 成功 doubao_search · 1,622 ms
豆包搜索结果（原始查询:HLB lirafugratinib Elevar FDA NDA cholangiocarcinoma stock reaction filing acceptance；API SearchType:web） - kb_search 降级 stock_tools HTTP · 4,359 ms
{
原文全文
展开原文 · 4,049 字
HLB Files for European Approval of Bile Duct Cancer Drug - Seoul Economic Daily
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
HLB (028300.KS) has begun the European approval process for lirafugratinib, its bile duct cancer drug candidate, following an earlier filing in the United States.
Elevar Therapeutics, HLB's U.S. subsidiary, submitted a marketing authorization application for lirafugratinib to the European Medicines Agency on the 14th as a second-line treatment for FGFR2-driven advanced and metastatic bile duct cancer, HLB said on the 15th.
The application is based on results from a global Phase 1/2 trial conducted by Elevar. According to HLB, patients with FGFR2 fusion-positive advanced or metastatic cholangiocarcinoma who had received at least one prior systemic therapy showed an objective response rate of 46.5% on lirafugratinib. Median duration of response was 11.8 months, median progression-free survival was 11.3 months and median overall survival was 22.8 months.
Lirafugratinib received orphan drug designation from the U.S. Food and Drug Administration in 2022 and breakthrough therapy designation in 2023. Elevar filed a new drug application with the FDA in January this year, with a review deadline of the 25th of this month.
Elevar is also running trials aimed at broadening the drug's use. A global Phase 2 study is under way in patients with a range of solid tumors carrying FGFR2 mutations. Patient enrollment and dosing are proceeding at trial sites in South Korea, the United States, Britain and Europe, with an interim analysis targeted for next year.
"Lirafugratinib is a drug candidate for which we have confirmed clinically meaningful treatment effects and differentiated safety data," Elevar CEO Kim Dong-gun said. "We will proceed with the approval processes in the United States and Europe without setbacks, while expanding lirafugratinib's therapeutic potential to a range of solid tumors through tumor-agnostic trials."
#
HLB
#
Lirafugratinib
#
ElevarTherapeutics
#
BileDuctCancer
#
FGFR2
#
EMA
#
Biotech
Original reporting by
Han Tae-hee
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
4:02
High Yield, Low Return: Korea's Covered Call ETF Reality Check | September 15 2026
4:02
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
HLB (028300.KS) has begun the European approval process for lirafugratinib, its bile duct cancer drug candidate, following an earlier filing in the United States.
Elevar Therapeutics, HLB's U.S. subsidiary, submitted a marketing authorization application for lirafugratinib to the European Medicines Agency on the 14th as a second-line treatment for FGFR2-driven advanced and metastatic bile duct cancer, HLB said on the 15th.
The application is based on results from a global Phase 1/2 trial conducted by Elevar. According to HLB, patients with FGFR2 fusion-positive advanced or metastatic cholangiocarcinoma who had received at least one prior systemic therapy showed an objective response rate of 46.5% on lirafugratinib. Median duration of response was 11.8 months, median progression-free survival was 11.3 months and median overall survival was 22.8 months.
Lirafugratinib received orphan drug designation from the U.S. Food and Drug Administration in 2022 and breakthrough therapy designation in 2023. Elevar filed a new drug application with the FDA in January this year, with a review deadline of the 25th of this month.
Elevar is also running trials aimed at broadening the drug's use. A global Phase 2 study is under way in patients with a range of solid tumors carrying FGFR2 mutations. Patient enrollment and dosing are proceeding at trial sites in South Korea, the United States, Britain and Europe, with an interim analysis targeted for next year.
"Lirafugratinib is a drug candidate for which we have confirmed clinically meaningful treatment effects and differentiated safety data," Elevar CEO Kim Dong-gun said. "We will proceed with the approval processes in the United States and Europe without setbacks, while expanding lirafugratinib's therapeutic potential to a range of solid tumors through tumor-agnostic trials."
#
HLB
#
Lirafugratinib
#
ElevarTherapeutics
#
BileDuctCancer
#
FGFR2
#
EMA
#
Biotech
Original reporting by
Han Tae-hee
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
4:02
High Yield, Low Return: Korea's Covered Call ETF Reality Check | September 15 2026
4:02
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。